Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Gross Margin (2016 - 2025)

Ligand Pharmaceuticals' Gross Margin history spans 16 years, with the latest figure at 94.99% for Q4 2025.

  • For Q4 2025, Gross Margin rose 161.0% year-over-year to 94.99%; the TTM value through Dec 2025 reached 94.57%, up 120.0%, while the annual FY2025 figure was 94.57%, 120.0% up from the prior year.
  • Gross Margin for Q4 2025 was 94.99% at Ligand Pharmaceuticals, down from 96.71% in the prior quarter.
  • Across five years, Gross Margin topped out at 96.71% in Q3 2025 and bottomed at 57.1% in Q4 2022.
  • The 5-year median for Gross Margin is 90.05% (2023), against an average of 85.75%.
  • The largest annual shift saw Gross Margin crashed -2165bps in 2022 before it skyrocketed 3706bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 78.75% in 2021, then decreased by -27bps to 57.1% in 2022, then skyrocketed by 65bps to 94.16% in 2023, then dropped by -1bps to 93.37% in 2024, then rose by 2bps to 94.99% in 2025.
  • Per Business Quant, the three most recent readings for LGND's Gross Margin are 94.99% (Q4 2025), 96.71% (Q3 2025), and 93.9% (Q2 2025).